Abstract: PO1437
Healthcare Resource Utilization and Costs over 5 Years for a Systemic Lupus Erythematosus (SLE) Cohort Newly Diagnosed with Lupus Nephritis: Evidence from a US Administrative Claims Database
Session Information
- Glomerular Diseases: Immunology and Inflammation in Vasculitis and Lupus Nephritis
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1202 Glomerular Diseases: Immunology and Inflammation
Authors
- Bell, Christopher F., US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, North Carolina, United States
- Chastek, Benjamin, Optum, Eden Prairie, Minnesota, United States
- Rubin, Bernie, GlaxoSmithKline, Philadelphia, Pennsylvania, United States
- Huang, Shirley, US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, North Carolina, United States
Background
Lupus nephritis (LN) occurs in ~40% of adults with SLE. Despite the high burden of LN, current care management and utilization data are limited. This longitudinal study evaluated US healthcare resource utilization (HRU) and costs over 5 years in patients (pts) with SLE newly diagnosed with LN.
Methods
This retrospective cohort study (GSK Study 214102) used data from the Optum Research Database. Index date was the first claim with a renal diagnosis code indicating LN during the identification period (Aug 1, 2011−Jul 31, 2018). Inclusion criteria: age ≥18 years; ≥2 renal diagnosis codes during the identification period; ≥1 inpatient or ≥2 outpatient SLE diagnosis codes in the 12 months pre index; and continuous enrollment of ≥12 months pre and post index. HRU and costs for the cohort with 5 years of continuous enrollment post index are reported.
Results
Overall, 2159 pts met the study criteria (mean [standard deviation, SD] age, 58.5 [14.9] years; 86.7% female) and 335 had ≥5 years of continuous enrollment post index. HRU and costs were highest in the first year post LN diagnosis (Figure). Mean healthcare costs were $44,205 in Year 1 and ~$30,000/year in Years 2 through 5. Approximately 50% of patients incurred an inpatient stay in Year 1, with ~25% of patients hospitalized in each subsequent year.
Conclusion
Patients with newly diagnosed LN incur substantial HRU and costs, which were highest in the year of diagnosis. These data highlight the need for interventions to prevent renal worsening in SLE.
Figure. Longitudinal HRU and costs among patients with ≥5 years of follow-up (N=335)
Funding
- Commercial Support –